Mochida Pharma President Announces Niche Expansion And Aims For ¥3 Billion Annul Revenue From Generic Drugs
This article was originally published in PharmAsia News
Executive Summary
Segmentation in the pharmaceutical industry creates many areas for mid-sized drug makers to explore, Mochida Pharma President Naoyuki Mochida stated at a press briefing. As a mid-sized enterprise, Mochida's niche in speed and specialization will allow it to compete with industrial giants, Mochida said. In 2008, Mochida Pharma will focus resources on four areas: cardiovascular drugs, obstetrics and gynecology, dermatological treatment and emergency medicines. Establishing strategic alliances with other pharmaceutical companies also creates opportunities to expand. Last February, Mochida Pharma signed a contract with Norvatis to jointly promote the anti-hypertension drug Diovan (valsartan). Regarding the company's generic drug business, Mr. Mochida expects to have a wider selection in products and has a goal of ¥3 billion in annual revenue. (Click here for more-Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.